A Multicenter, Phase Ib Study of Subcutaneous Administration of Isatuximab in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed/refractory Multiple Myeloma

Overview

Journal Haematologica

Specialty Hematology

Date 2024 Aug 19

PMID 39157871

Authors

Hang Quach

Gurdeep Parmar

Enrique M Ocio

H Miles Prince

Albert Oriol

Helen Crowther

Nobuhiro Tsukada

Pierre Bories

Sumit Madan

Nitya Nathwani

Kazutaka Sunami

Dorothee Semiond

Disa Yu

Paul Cordero

Sandrine Mace

Florence Suzan

Philippe Moreau

Affiliations

Soon will be listed here.

References

OShaughnessy J, Sousa S, Cruz J, Fallowfield L, Auvinen P, Pulido C . Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study. Eur J Cancer. 2021; 152:223-232. DOI: 10.1016/j.ejca.2021.03.047. View

Richardson P, Perrot A, San-Miguel J, Beksac M, Spicka I, Leleu X . Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. Lancet Oncol. 2022; 23(3):416-427. DOI: 10.1016/S1470-2045(22)00019-5. View

McCloskey C, Ortega M, Nair S, Garcia M, Manevy F . A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting. Pharmacoecon Open. 2022; 7(1):3-36. PMC: 9395845. DOI: 10.1007/s41669-022-00361-3. View

Kumar S, Paiva B, Anderson K, Durie B, Landgren O, Moreau P . International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17(8):e328-e346. DOI: 10.1016/S1470-2045(16)30206-6. View

Leleu X, Martin T, Weisel K, Schjesvold F, Iida S, Malavasi F . Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes. Ann Hematol. 2022; 101(10):2123-2137. PMC: 9463192. DOI: 10.1007/s00277-022-04917-5. View

Cowan A, Green D, Kwok M, Lee S, Coffey D, Holmberg L . Diagnosis and Management of Multiple Myeloma: A Review. JAMA. 2022; 327(5):464-477. DOI: 10.1001/jama.2022.0003. View

Usmani S, Mateos M, Hungria V, Iida S, Bahlis N, Nahi H . Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results. J Cancer Res Clin Oncol. 2020; 147(2):619-631. DOI: 10.1007/s00432-020-03365-w. View

Bittner B, Richter W, Schmidt J . Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities. BioDrugs. 2018; 32(5):425-440. PMC: 6182494. DOI: 10.1007/s40259-018-0295-0. View

Rachedi F, Koiwai K, Gaudel-Dedieu N, Sebastien B, Thai H, Brillac C . Exposure-response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma. CPT Pharmacometrics Syst Pharmacol. 2022; 11(6):766-777. PMC: 9197531. DOI: 10.1002/psp4.12789. View

10.

Moreau P, Dimopoulos M, Mikhael J, Yong K, Capra M, Facon T . Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021; 397(10292):2361-2371. DOI: 10.1016/S0140-6736(21)00592-4. View

11.

Attal M, Richardson P, Rajkumar S, San-Miguel J, Beksac M, Spicka I . Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019; 394(10214):2096-2107. DOI: 10.1016/S0140-6736(19)32556-5. View